Erasca, Inc. ERAS R2K
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Profit CAGR of 16.2% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 42.9% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ERAS Erasca, Inc. R2K | 12.84 | - | $3.99B | - | -35.74% | -69.86% | - | 16.24% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 35.63M | 30.62M | 32.55M | 32.60M | 37.91M |
| Operating Income | - | -7.28M | -11.16M | -19.61M | -28.18M | -46.04M | -36.51M | -35.91M | -36.96M | -37.02M | -35.97M | -34.66M | -38.85M | -67.78M | -37.24M | - | -35.63M | -30.62M | -32.55M | -32.60M | -37.91M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -34.81M | -29.84M | -31.79M | -31.86M | -37.19M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -30.97M | -33.88M | -30.61M | -29.09M | -183.44M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -23.66M | -5.49M | -10.61M | -18.02M | -28.21M | -46.07M | -36.46M | -35.61M | -35.49M | -33.20M | -31.78M | -30.36M | -35.02M | -63.20M | -31.20M | - | -30.97M | -33.88M | -30.61M | -29.09M | -183.44M |
| Diluted EPS | - | - | - | - | -1.20 | -0.46 | -0.31 | -0.30 | -0.29 | -0.22 | -0.21 | -0.20 | -0.23 | -0.29 | -0.11 | - | -0.11 | -0.12 | -0.11 | -0.10 | -0.60 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | - | 145.45M | 141.53M | 157.09M | 131.41M |
| Operating Income | -109.25M | - | -145.45M | -141.53M | -157.09M | -131.41M |
| EBITDA | - | - | -142.81M | -137.79M | -153.28M | -128.30M |
| Interest Expense | - | - | - | - | - | - |
| Pretax Income | - | - | -242.81M | -125.04M | -161.65M | -124.55M |
| Tax Provision | - | - | - | - | - | - |
| Net Income | -101.66M | - | -242.81M | -125.04M | -161.65M | -124.55M |
| Diluted EPS | - | - | -1.99 | -0.83 | -0.69 | -0.44 |
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | 16.24% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +817.14% |
| 6 Months: | +318.24% |
| 3 Months: | -6.00% |
| 1 Month: | +40.94% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 124.83M | - | 514.91M | 395.30M | 502.53M | 396.15M |
| Current Assets | - | - | - | 444.50M | 320.68M | 308.79M | 286.24M |
| Cash & Equivalents | - | 65.38M | - | 284.22M | 93.08M | 67.74M | 73.81M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - |
| Total Liabilities | - | 17.40M | - | 103.06M | 78.61M | 79.03M | 70.98M |
| Current Liabilities | - | 13.68M | - | 48.69M | 26.16M | 31.39M | 28.51M |
| Long Term Debt | - | - | - | - | - | - | - |
| Total Debt | - | - | - | 55.10M | 55.86M | 51.89M | 47.14M |
| Total Equity | -13.60M | -113.98M | - | 411.85M | 316.69M | 423.50M | 325.17M |
| Shares Outstanding | - | - | - | 149.33M | 151.46M | 283.22M | 284.16M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -32.69M | - | -103.26M | -101.22M | -109.42M | -95.45M |
| Investing Cash Flow | -71.20M | - | -71.08M | -91.22M | -156.62M | 100.42M |
| Financing Cash Flow | 139.99M | - | 98.08M | 1.29M | 240.70M | 1.10M |
| Capital Expenditure | -947.00K | - | -16.55M | -21.77M | -22.56M | -9.63M |
| Free Cash Flow | -33.63M | - | -119.81M | -122.99M | -131.98M | -105.08M |
| Net Change in Cash | - | - | -76.27M | -191.14M | -25.34M | 6.07M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | 89.2% | - | -59.0% | -39.5% | -38.2% | -38.3% |
| ROCE % | -98.3% | - | -31.2% | -38.3% | -33.3% | -35.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Frazier Life Sciences Management, L.P. | 7.93% | 24.68M | $316.83M |
| 2 | T. Rowe Price Investment Management, Inc. | 6.84% | 21.26M | $272.97M |
| 3 | Blackrock Inc. | 6.48% | 20.15M | $258.74M |
| 4 | Venrock Adviser, LLC | 5.27% | 16.38M | $210.36M |
| 5 | RTW Investments LP | 5.20% | 16.16M | $207.46M |
| 6 | Vivo Capital, LLC | 3.91% | 12.15M | $156.03M |
| 7 | Vanguard Capital Management LLC | 3.62% | 11.25M | $144.45M |
| 8 | Siren, L.L.C. | 3.62% | 11.24M | $144.38M |
| 9 | Logos Global Management LP | 3.59% | 11.15M | $143.17M |
| 10 | Paradigm Biocapital Advisors LP | 3.34% | 10.39M | $133.44M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ERAS